Who are Platinum-based doublet chemotherapy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/platinum-based-doublet-chemotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Platinum-based doublet chemotherapy — Competitive Intelligence Brief

Platinum-based doublet chemotherapy (Platinum-based doublet chemotherapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platinum-based chemotherapy doublet. Area: Oncology.

marketed Platinum-based chemotherapy doublet DNA (platinum-DNA adducts) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Platinum-based doublet chemotherapy (Platinum-based doublet chemotherapy) — The First Hospital of Hebei Medical University. Platinum-based doublet chemotherapy uses two chemotherapy agents containing platinum to cross-link DNA and prevent cancer cell replication.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Platinum-based doublet chemotherapy TARGET	Platinum-based doublet chemotherapy	The First Hospital of Hebei Medical University	marketed	Platinum-based chemotherapy doublet	DNA (platinum-DNA adducts)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Platinum-based chemotherapy doublet class)

The First Hospital of Hebei Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Platinum-based doublet chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/platinum-based-doublet-chemotherapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab